Clinical Characteristics of 10 Chinese Patients with Melorheostosis and Identification of a Somatic MAP2K1 Variant in One Case

Overview

Journal Mol Genet Genomic Med

Specialty Genetics

Date 2022 Aug 25

PMID 36004822

Authors

Xiaojun Han

Yang Xu

Zhanying Wei

Chun Wang

Hua Yue

Zhenlin Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Melorheostosis (MEL) is an exceptionally rare sclerosing bone dysplasia with asymmetrically exuberant bone formation and soft tissue lesions in a segmental distribution. We aimed to summarize the clinical characteristics of Chinese MEL patients and identify their pathogenic cause.

Methods: In total, 10 Chinese MEL patients were recruited, and clinical manifestations and radiological characteristics were recorded. Sanger sequencing of the LEMD3 gene was performed on peripheral blood samples of all patients, while the exome sequencing of matched peripheral blood, melorheostotic bone, and skin lesion samples was conducted on one patient who provided affected bone and skin tissues. Micro-computed tomography (micro-CT) was also used to scan the melorheostotic bone tissue.

Results: We found the average age of the 10 MEL patients was 29.5 years (range 11-40 years), and the major symptoms were bone pain, restricted movement, and bone deformity. The lesions sites were mainly located in femur (8/10), tibia (8/10), fibula (6/10), and foot (7/10), the next was pelvis (4/10), and the last were patella (1/10), hand (1/10) and spine (1/10). Radiological examinations showed a mixture of hyperostosis consisting of classic "dripping candle wax," "osteoma-like," or "myositis ossificans-like" patterns in most patients. No germline pathogenic variants in the LEMD3 gene were found in all patients, but a disease-causing somatic variant of MAP2K1 (c.167A > C, p.Gln56Pro) was detected in melorheostotic bone from one patient. Moreover, the micro-CT analysis showed increased porosity in the melorheostotic bone with somatic MAP2K1 variant.

Conclusion: This is a summary of the clinical characteristics of Chinese MEL patients and we first identify the somatic MAP2K1 variant in Chinese patients. Our findings validate the molecular genetic mechanism of MEL and broaden its phenotype spectrum in the Chinese population.

Citing Articles

Clinical characteristics of 10 Chinese patients with melorheostosis and identification of a somatic MAP2K1 variant in one case.

Han X, Xu Y, Wei Z, Wang C, Yue H, Zhang Z Mol Genet Genomic Med. 2022; 10(10):e2043.

PMID: 36004822 PMC: 9544224. DOI: 10.1002/mgg3.2043.

References

Jha S, Fratzl-Zelman N, Roschger P, Papadakis G, Cowen E, Kang H . Distinct Clinical and Pathological Features of Melorheostosis Associated With Somatic MAP2K1 Mutations. J Bone Miner Res. 2018; 34(1):145-156. PMC: 7577747. DOI: 10.1002/jbmr.3577. View

Mumm S, Wenkert D, Zhang X, McAlister W, Mier R, Whyte M . Deactivating germline mutations in LEMD3 cause osteopoikilosis and Buschke-Ollendorff syndrome, but not sporadic melorheostosis. J Bone Miner Res. 2006; 22(2):243-50. DOI: 10.1359/jbmr.061102. View

Woolridge B, Stone N, Denic N . Melorheostosis isolated to the calcaneus: a case report and review of the literature. Foot Ankle Int. 2005; 26(8):660-3. DOI: 10.1177/107110070502600814. View

Wordsworth P, Chan M . Melorheostosis and Osteopoikilosis: A Review of Clinical Features and Pathogenesis. Calcif Tissue Int. 2019; 104(5):530-543. DOI: 10.1007/s00223-019-00543-y. View

Couto A, Bruges-Armas J, Peach C, Chapman K, Brown M, Wordsworth B . A novel LEMD3 mutation common to patients with osteopoikilosis with and without melorheostosis. Calcif Tissue Int. 2007; 81(2):81-4. DOI: 10.1007/s00223-007-9043-z. View

De Ridder R, Boudin E, Zillikens M, Ibrahim J, van der Eerden B, Van Hul W . A multi-omics approach expands the mutational spectrum of MAP2K1-related melorheostosis. Bone. 2020; 137:115406. DOI: 10.1016/j.bone.2020.115406. View

Kotwal A, Clarke B . Melorheostosis: a Rare Sclerosing Bone Dysplasia. Curr Osteoporos Rep. 2017; 15(4):335-342. DOI: 10.1007/s11914-017-0375-y. View

Fratzl-Zelman N, Roschger P, Kang H, Jha S, Roschger A, Blouin S . Melorheostotic Bone Lesions Caused by Somatic Mutations in MAP2K1 Have Deteriorated Microarchitecture and Periosteal Reaction. J Bone Miner Res. 2019; 34(5):883-895. PMC: 8302214. DOI: 10.1002/jbmr.3656. View

Cohen-Solal K, Boregowda R, Lasfar A . RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression. Mol Cancer. 2015; 14:137. PMC: 4513933. DOI: 10.1186/s12943-015-0404-3. View

10.

Ihde L, Forrester D, Gottsegen C, Masih S, Patel D, Vachon L . Sclerosing bone dysplasias: review and differentiation from other causes of osteosclerosis. Radiographics. 2011; 31(7):1865-82. DOI: 10.1148/rg.317115093. View

11.

Kang H, Jha S, Deng Z, Fratzl-Zelman N, Cabral W, Ivovic A . Somatic activating mutations in MAP2K1 cause melorheostosis. Nat Commun. 2018; 9(1):1390. PMC: 5895796. DOI: 10.1038/s41467-018-03720-z. View

12.

WYNNE-DAVIES R, Gormley J . The prevalence of skeletal dysplasias. An estimate of their minimum frequency and the number of patients requiring orthopaedic care. J Bone Joint Surg Br. 1985; 67(1):133-7. DOI: 10.1302/0301-620X.67B1.3155744. View

13.

Ethunandan M, Khosla N, Tilley E, Webb A . Melorheostosis involving the craniofacial skeleton. J Craniofac Surg. 2004; 15(6):1062-5. DOI: 10.1097/00001665-200411000-00038. View

14.

Han X, Xu Y, Wei Z, Wang C, Yue H, Zhang Z . Clinical characteristics of 10 Chinese patients with melorheostosis and identification of a somatic MAP2K1 variant in one case. Mol Genet Genomic Med. 2022; 10(10):e2043. PMC: 9544224. DOI: 10.1002/mgg3.2043. View

15.

Whyte M, Griffith M, Trani L, Mumm S, Gottesman G, McAlister W . Melorheostosis: Exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRAS. Bone. 2017; 101:145-155. PMC: 5518630. DOI: 10.1016/j.bone.2017.04.010. View

16.

Lin F, Morrison J, Wu W, Worman H . MAN1, an integral protein of the inner nuclear membrane, binds Smad2 and Smad3 and antagonizes transforming growth factor-beta signaling. Hum Mol Genet. 2004; 14(3):437-45. DOI: 10.1093/hmg/ddi040. View

17.

Vivekanandhan S, Mukhopadhyay D . Genetic status of KRAS influences Transforming Growth Factor-beta (TGF-β) signaling: An insight into Neuropilin-1 (NRP1) mediated tumorigenesis. Semin Cancer Biol. 2018; 54:72-79. PMC: 6072630. DOI: 10.1016/j.semcancer.2018.01.014. View

18.

Kang H, Jha S, Ivovic A, Fratzl-Zelman N, Deng Z, Mitra A . Somatic SMAD3-activating mutations cause melorheostosis by up-regulating the TGF-β/SMAD pathway. J Exp Med. 2020; 217(5). PMC: 7201932. DOI: 10.1084/jem.20191499. View

19.

Freyschmidt J . Melorheostosis: a review of 23 cases. Eur Radiol. 2001; 11(3):474-9. DOI: 10.1007/s003300000562. View

20.

Mortier G, Cohn D, Cormier-Daire V, Hall C, Krakow D, Mundlos S . Nosology and classification of genetic skeletal disorders: 2019 revision. Am J Med Genet A. 2019; 179(12):2393-2419. DOI: 10.1002/ajmg.a.61366. View